Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Dise… Read more
Market Cap & Net Worth: Supernus Pharmaceuticals Inc (SUPN)
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has a market capitalization of $2.88 Billion ($2.88 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4278 globally and #2694 in its home market, demonstrating a -6.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Supernus Pharmaceuticals Inc's stock price $50.21 by its total outstanding shares 57339350 (57.34 Million).
Supernus Pharmaceuticals Inc Market Cap History: 2015 to 2026
Supernus Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $770.64 Million to $2.88 Billion (10.72% CAGR).
Index Memberships
Supernus Pharmaceuticals Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.12% | #112 of 976 |
|
NASDAQ Composite
IXIC
|
$33.26 Trillion | 0.01% | #524 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.17% | #68 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.35 Trillion | 0.15% | #205 of 602 |
Weight: Supernus Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Supernus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Supernus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.13x
Supernus Pharmaceuticals Inc's market cap is 3.13 times its annual revenue
0.72x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
28.07x
Supernus Pharmaceuticals Inc's market cap is 28.07 times its annual earnings
6.13x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $770.64 Million | $144.43 Million | $14.02 Million | 5.34x | 54.98x |
| 2016 | $1.45 Billion | $215.00 Million | $91.22 Million | 6.73x | 15.87x |
| 2017 | $2.28 Billion | $302.24 Million | $57.28 Million | 7.56x | 39.89x |
| 2018 | $1.90 Billion | $408.90 Million | $110.99 Million | 4.66x | 17.16x |
| 2019 | $1.36 Billion | $392.75 Million | $113.06 Million | 3.46x | 12.03x |
| 2020 | $1.44 Billion | $520.40 Million | $126.95 Million | 2.77x | 11.36x |
| 2021 | $1.67 Billion | $579.77 Million | $53.42 Million | 2.88x | 31.30x |
| 2022 | $2.05 Billion | $667.24 Million | $60.71 Million | 3.07x | 33.69x |
| 2023 | $1.66 Billion | $607.52 Million | $1.32 Million | 2.73x | 1260.94x |
| 2024 | $2.07 Billion | $661.82 Million | $73.86 Million | 3.13x | 28.07x |
Competitor Companies of SUPN by Market Capitalization
Companies near Supernus Pharmaceuticals Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Supernus Pharmaceuticals Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Supernus Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Supernus Pharmaceuticals Inc's market cap moved from $770.64 Million to $ 2.88 Billion, with a yearly change of 10.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.88 Billion | +1.03% |
| 2025 | $2.85 Billion | +37.44% |
| 2024 | $2.07 Billion | +24.95% |
| 2023 | $1.66 Billion | -18.87% |
| 2022 | $2.05 Billion | +22.33% |
| 2021 | $1.67 Billion | +15.90% |
| 2020 | $1.44 Billion | +6.07% |
| 2019 | $1.36 Billion | -28.60% |
| 2018 | $1.90 Billion | -16.64% |
| 2017 | $2.28 Billion | +57.82% |
| 2016 | $1.45 Billion | +87.87% |
| 2015 | $770.64 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Supernus Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.88 Billion USD |
| MoneyControl | $2.88 Billion USD |
| MarketWatch | $2.88 Billion USD |
| marketcap.company | $2.88 Billion USD |
| Reuters | $2.88 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.